Concomitant Ruxolitinib Induction and Maintenance With Cytarabine Based Chemotherapy in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary) ; Ruxolitinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 07 Sep 2018 Planned End Date changed from 1 Mar 2022 to 31 Dec 2021.
- 07 Sep 2018 Planned primary completion date changed from 1 Mar 2020 to 31 Dec 2021.
- 22 Jun 2018 New trial record